ATE343575T1 - Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz - Google Patents
Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerzInfo
- Publication number
- ATE343575T1 ATE343575T1 AT02799606T AT02799606T ATE343575T1 AT E343575 T1 ATE343575 T1 AT E343575T1 AT 02799606 T AT02799606 T AT 02799606T AT 02799606 T AT02799606 T AT 02799606T AT E343575 T1 ATE343575 T1 AT E343575T1
- Authority
- AT
- Austria
- Prior art keywords
- chronic pain
- derivatives
- cancer
- azaoxoindole
- treatment
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title abstract 3
- 208000000094 Chronic Pain Diseases 0.000 title abstract 2
- 206010058019 Cancer Pain Diseases 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical class C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003226 mitogen Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 125000004095 oxindolyl group Chemical class N1(C(CC2=CC=CC=C12)=O)* 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32601201P | 2001-09-27 | 2001-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE343575T1 true ATE343575T1 (de) | 2006-11-15 |
Family
ID=23270442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02799606T ATE343575T1 (de) | 2001-09-27 | 2002-09-24 | Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7015231B2 (de) |
| EP (1) | EP1430053B1 (de) |
| JP (1) | JP2005508337A (de) |
| AT (1) | ATE343575T1 (de) |
| DE (1) | DE60215682T2 (de) |
| ES (1) | ES2275021T3 (de) |
| WO (1) | WO2003027111A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002020479A1 (en) | 2000-09-01 | 2002-03-14 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| AU8664701A (en) | 2000-09-01 | 2002-03-22 | Glaxo Group Ltd | Oxindole derivatives |
| EP1430053B1 (de) * | 2001-09-27 | 2006-10-25 | SmithKline Beecham Corporation | AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ |
| NZ561145A (en) | 2005-02-04 | 2011-02-25 | Astrazeneca Ab | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
| AU2006215386B2 (en) | 2005-02-16 | 2009-06-11 | Astrazeneca Ab | Chemical compounds |
| WO2006087538A1 (en) * | 2005-02-16 | 2006-08-24 | Astrazeneca Ab | Chemical compounds |
| RU2463302C2 (ru) | 2005-10-28 | 2012-10-10 | Астразенека Аб | Производные 4-(3-аминопиразол)пиримидина для применения в качестве ингибиторов тирозинкиназы для лечения злокачественного новообразования |
| US7514435B2 (en) * | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| CN101426774B (zh) | 2006-04-19 | 2012-04-25 | 安斯泰来制药有限公司 | 唑类甲酰胺衍生物 |
| US8304547B2 (en) | 2007-10-24 | 2012-11-06 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| US8426673B2 (en) | 2008-01-11 | 2013-04-23 | Astellas Pharma, Inc. | Pathological animal model for pelvic pain syndrome |
| WO2010077680A2 (en) | 2008-12-08 | 2010-07-08 | Vm Discovery Inc. | Compositions of protein receptor tyrosine kinase inhibitors |
| JP5778755B2 (ja) * | 2010-04-15 | 2015-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ヒドロキノンの製造方法 |
| US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
| CN103804273B (zh) * | 2014-01-27 | 2016-06-15 | 贵州大学 | 氧化吲哚与茚三酮双季碳拼接衍生物及其制备方法 |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| MA39286A (fr) | 2014-09-17 | 2016-03-24 | Mundipharma International Corporation Ltd | Formes cristallines d'inhibiteurs de la tyrosine kinase et leurs sels |
| CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
| WO2017106492A1 (en) | 2015-12-18 | 2017-06-22 | Ignyta, Inc. | Combinations for the treatment of cancer |
| EP3654952A1 (de) | 2017-07-19 | 2020-05-27 | Ignyta, Inc. | Pharmazeutische zusammensetzungen mit entrectinib |
| CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9423997D0 (en) * | 1994-11-28 | 1995-01-11 | Erba Carlo Spa | Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| JP2002522452A (ja) | 1998-08-04 | 2002-07-23 | スージェン・インコーポレーテッド | 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン |
| EP1430053B1 (de) * | 2001-09-27 | 2006-10-25 | SmithKline Beecham Corporation | AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ |
-
2002
- 2002-09-24 EP EP02799606A patent/EP1430053B1/de not_active Expired - Lifetime
- 2002-09-24 ES ES02799606T patent/ES2275021T3/es not_active Expired - Lifetime
- 2002-09-24 AT AT02799606T patent/ATE343575T1/de not_active IP Right Cessation
- 2002-09-24 DE DE60215682T patent/DE60215682T2/de not_active Expired - Fee Related
- 2002-09-24 JP JP2003530699A patent/JP2005508337A/ja active Pending
- 2002-09-24 US US10/490,831 patent/US7015231B2/en not_active Expired - Fee Related
- 2002-09-24 WO PCT/US2002/030150 patent/WO2003027111A1/en not_active Ceased
-
2006
- 2006-01-20 US US11/336,010 patent/US20060128745A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005508337A (ja) | 2005-03-31 |
| US7015231B2 (en) | 2006-03-21 |
| EP1430053A1 (de) | 2004-06-23 |
| US20060128745A1 (en) | 2006-06-15 |
| EP1430053B1 (de) | 2006-10-25 |
| DE60215682D1 (de) | 2006-12-07 |
| ES2275021T3 (es) | 2007-06-01 |
| WO2003027111A1 (en) | 2003-04-03 |
| US20040198766A1 (en) | 2004-10-07 |
| DE60215682T2 (de) | 2007-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE343575T1 (de) | Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz | |
| ATE240328T1 (de) | Substituierte azaoxindolederivate | |
| MY134783A (en) | Rho-kinase inhibitors | |
| MY142915A (en) | Rho-kinase inhibitors | |
| ATE381557T1 (de) | Rho-kinase inhibitoren | |
| YU61402A (sh) | Pirol substituisani 2 indolinon protein kinazni inhibitori | |
| ATE419253T1 (de) | Inhibitoren von thienopyridin- und furopyridinkinase | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| DE60208792D1 (de) | Tyrosin-kinase inhibitoren | |
| ATE473980T1 (de) | Triazolopyridazine als proteinkinase-inhibitoren | |
| ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| ATE525375T1 (de) | Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1 | |
| HN2004000150A (es) | Pirazoles como inhibidores de factor de necrosis tumoral | |
| DE60118889D1 (de) | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs | |
| ATE424208T1 (de) | Proteinkinaseinhibitoren | |
| DE60106409D1 (de) | 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen | |
| ATE482217T1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| ATE321572T1 (de) | Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren | |
| DE60215947D1 (de) | Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht | |
| DK1687642T3 (da) | Screeningsfremgangsmåder til kombinationer af biologiske forbindelser | |
| ATE540951T1 (de) | Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |